Gt biopharma reports second quarter fiscal 2022 financial results and business update

Brisbane, calif., aug. 11, 2022 (globe newswire) -- gt biopharma, inc. (the “company” or “gtb”) (nasdaq: gtbp), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the company's proprietary natural killer (nk) cell engager, trike® platform, today announced second quarter fiscal 2022 results for the period ended june 30, 2022.

GTBP Ratings Summary

GTBP Quant Ranking